Literatur
-
1
Connolly S J, Ezekowitz M D, Yusuf S. et al .
Dabigatran versus warfarin
in patients with atrial fibrillation.
N Engl J Med.
2009;
361
1139-1151
-
2
Eichhorst B, Busch R, Stilgenbauer S.
First-line therapy with fludarabine compared with chlorambucil
does not result in a major benfit for elderly patients with advanced
chronic lymphocytic leukemia.
Blood.
2009;
114
3382-3391
-
3
Fenaux P, Mufti G J, Hellström-Lindberg E. et al .
Efficacy of azacitidine
compared with that of conventional care regimens in the treatment
of higher-risk myelodysplastic syndromes: a randomised, open-label, phase
III study.
Lancet Oncol.
2009;
10
223-232
-
4
Hallek M, Fingerle-Fowson, Fink A -M. et al .
First-line treatment wih Fludarabine (F), Cyclophosphamide
(C), and Rituximab (R) (FCR) improves overall survival (OS) in previously
untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL):
results of a randomized phase III trial on behalf of an international
roup of investigators and the German CLL study group.
Blood.
2009;
114
223
(Abstract 535)
-
5
Hulin C, Facon T, Rodon P. et
al .
Efficacy of Melphalan and Prednisone Plus Thalidomide
in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma:
IFM 01/01 Trial.
J Clin Oncol.
2009;
27
3664-3670
-
6
Morel P, Duhamel A, Gobbi P. et
al .
International prognostic scoring system for Waldenström
macroglobulinemia.
Blood.
2009;
119
4163-4170
-
7
Rajkumar S V, Jacobus S, Callander N S. et al .
Lenalidomide plus high-dose dexamethasone
versus lenalidomide plus low-dose dexamethasone as initial therapy
for newly diagnosed multiple myeloma: an open-label randomised controlled
trial.
Lancet Oncol.
2010;
11
29-37
-
8
Robak T, Dmoszynska A, Solal-Céligny P. et al .
Rituximab Plus Fludarabine
and Cyclophosphamide Prolongs Progression-Free Survival Compared
With Fludarabine and Cyclophosphamide Alone in Previously Treated
Chronic Lymphocytic Leukemia.
JCO.
2010;
28
1756-1765
-
9
Rummel M J, Niederle N, Maschmeyer G. et al .
Bendamustin plus rituximab is superior
in respect of progression free survival and CR rate when compared
to CHOP plus rituximab as first-line treatment of patients with
advanced follicular, indolent, and mantle cell lymphomas: Final
results of a randomized phase III study of the StiL.
Blood.
2009;
114
168
(Abstract 405)
-
10
San M iguel
JF, Schlag R, Khuageva N K. et al, VISTA Trial Investigators .
Bortezomib
plus melphalan and prednisone for initial treatment of multiple
myeloma.
N Engl J Med.
2008;
359
906-17
-
11
Schmitz N, Nickelsen M, Ziepert M. et al .
Aressive chemotherapy (CHOEP-14) and Rituximab
or high-dose therapy (MegaCHOEP) and Rituximab for young, high-risk
patients with aggressive B-cell lymphoma: results of the MegaCHOEP
trial of the German high-grade non-Hodgkin Lymphoma study group
(DSHNHL).
Blood.
2009;
114
168
(Abstract 404)
-
12
Schulman S, Kearon C, Kakkar A K. et al .
Dabigatran versus warfarin in the treatment of
acute venous thromboembolism.
N Engl J Med.
2009;
361
2342-2352
Prof. Dr. med. Martin Dreyling
Medizinische Klinik III der Universität München – Großhadern
Marchioninistraße 15
81337 München
Telefon: 089/7095-2202
Fax: 089/7095-2201
eMail: Martin.Dreyling@med.uni-muenchen.de
